Losartan 50 mg pharmacology
Pro Research Analysisby 
Searched over 200M research papers
Losartan 50 mg Pharmacology: Mechanism and Action Keywords
Losartan is a nonpeptide angiotensin II receptor antagonist, specifically blocking the type 1 angiotensin II (AT1) receptor. This action prevents angiotensin II from exerting its vasoconstrictive and aldosterone-secreting effects, leading to reduced blood pressure. Losartan is considered a selective and potent antihypertensive agent, offering a more targeted alternative to angiotensin-converting enzyme (ACE) inhibitors, with a similar efficacy profile in lowering blood pressure 1567.
Pharmacokinetics of Losartan 50 mg: Absorption, Metabolism, and Bioavailability
After oral administration, losartan is well absorbed and undergoes significant first-pass metabolism, primarily by the CYP2C9 enzyme, to form an active metabolite (EXP3174 or E3174), which is even more potent in blocking the AT1 receptor. The pharmacokinetic parameters, such as maximum plasma concentration (Cmax) and area under the curve (AUC), are consistent across different populations, with studies showing bioequivalence between generic and branded formulations, as well as between different ethnic groups (Asian Indian and Japanese) 13. The drug and its metabolite are both well tolerated, with no significant differences in pharmacokinetics due to ethnicity 13.
Dosage and Antihypertensive Efficacy of Losartan 50 mg
Clinical studies have shown that a 50 mg once-daily dose of losartan is the minimum effective dose for achieving significant, sustained reductions in blood pressure over a 24-hour period. Higher doses, such as 100 mg, do not provide substantially greater efficacy, indicating a plateau in the dose-response relationship. The antihypertensive effect of losartan 50 mg is comparable to that of other standard antihypertensive agents, including enalapril, felodipine, and atenolol 5678. The addition of low-dose hydrochlorothiazide (12.5 mg) to losartan 50 mg results in an additive antihypertensive effect 69.
Safety, Tolerability, and Drug Interactions
Losartan 50 mg is generally well tolerated, with a low incidence of adverse events similar to placebo. The most common side effect is mild dizziness. There is no evidence of rebound hypertension after discontinuation. When combined with other drugs, such as digoxin, losartan does not significantly alter their pharmacokinetics, indicating a low potential for drug-drug interactions 268. However, co-administration with CYP2C9 inhibitors like bucolome can reduce the formation of the active metabolite, potentially affecting efficacy .
Additional Pharmacological Effects
Beyond its antihypertensive action, losartan has shown beneficial effects in experimental models, such as reducing inflammation and tissue damage in chemotherapy-induced intestinal mucositis in mice, suggesting potential protective roles in other conditions .
Conclusion
Losartan 50 mg is a selective AT1 receptor blocker with proven efficacy and safety in the management of hypertension. It is well absorbed, metabolized to an active form, and demonstrates consistent pharmacokinetics and bioequivalence across populations. The 50 mg dose provides effective blood pressure control with a favorable safety profile and minimal drug interaction risk, making it a reliable choice for antihypertensive therapy.
Sources and full results
Most relevant research papers on this topic